Observational, Retrospective Analysis to Evaluate Switching to Raltegravir Plus Abacavir/Lamivudine in HIV-1-Infected Patients. ORASWIRAL Study
Latest Information Update: 14 Feb 2024
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ORASWIRAL
- 24 Jan 2017 Status changed to completed.
- 17 Mar 2016 New trial record